-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Korean scientists published an article in "ACS Nano" showing modern new drug discovery technology
Drug source analysis
Drug source analysisRecently, mRNA vaccines, ASO, and RNAi have been launched to speed up the entire RNA technology sector.
However, controlling the expression of multiple proteins does not mean that drugs cannot be made.
Today’s work uses a highly selective RNAi to inhibit a wide-ranging oncogenic RNA (miR21), so it is somewhat similar to epigenetic protein inhibitors such as EZH2
The MSA-Anti-21 produced by the reaction of MI-anti-21 with albumin in vivo is almost the same as the complex PK synthesized in vitro, indicating that the in vivo reaction is very efficient and free RNAi is immediately captured by albumin after entering the blood